Samir Narayan, MD | Trinity Health Michigan

Dr. Samir Narayan

Claim this profile

Saint Joseph Mercy Hospital

Studies Brain Tumor
Studies Breast Cancer
27 reported clinical trials
71 drugs studied

About Samir Narayan

Education:

  • MD from Wayne State University School of Medicine, Detroit, MI, USA.

Experience:

  • Completed Residency in Internal Medicine at Henry Ford Hospital, Detroit, MI, USA.
  • Undertook Fellowship in Gastroenterology at Henry Ford Hospital, Detroit, MI, USA.
  • Board-certified in Internal Medicine and Gastroenterology.

Area of expertise

1

Brain Tumor

Samir Narayan has run 6 trials for Brain Tumor. Some of their research focus areas include:

Stage IV
2

Breast Cancer

Samir Narayan has run 6 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
HER2 positive

Affiliated Hospitals

Image of trial facility.

Saint Joseph Mercy Hospital

Image of trial facility.

Trinity Health Saint Mary Mercy Livonia Hospital

Clinical Trials Samir Narayan is currently running

Image of trial facility.

Lomustine + Standard Therapy

for Glioblastoma

This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.

Recruiting

1 award

Phase 2 & 3

21 criteria

More about Samir Narayan

Clinical Trial Related

3 years of experience running clinical trials · Led 27 trials as a Principal Investigator · 16 Active Clinical Trials

Treatments Samir Narayan has experience with

  • Cisplatin
  • Radiation Therapy
  • Intensity-Modulated Radiation Therapy
  • Flutamide
  • Stereotactic Radiosurgery
  • Stereotactic Body Radiation Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Samir Narayan specialize in?

Is Samir Narayan currently recruiting for clinical trials?

Are there any treatments that Samir Narayan has studied deeply?

What is the best way to schedule an appointment with Samir Narayan?

What is the office address of Samir Narayan?

Is there any support for travel costs?